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Summary
The elimination of Mcl-1, an anti-apoptotic Bcl-2 fam-
ily member, is an early and required step for DNA
damage-induced apoptosis. The degradation of Mcl-1
can be blocked by proteasome inhibitors, suggesting
a role for the ubiquitin proteasome pathway in apopto-
sis. Here, we demonstrate that Mcl-1 is ubiquinated at
five lysines. Biochemical fractionation of cell extracts
allowed us to identify a 482 kDa HECT-domain-contain-
ing ubiquitin ligase named Mule (Mcl-1 ubiquitin ligase
E3) that is both required and sufficient for the poly-
ubiquitination of Mcl-1. Mule also contains a region
similar to the Bcl-2 homology region 3 (BH3) domain
that allows Mule to specifically interact with Mcl-1.
Elimination of Mule expression by RNA interference
stabilizes Mcl-1 protein, resulting in an attenuation of
the apoptosis induced by DNA-damage agents. Thus,
Mule is a unique BH3-containing E3 ubiquitin ligase
apical to Bcl-2 family proteins during DNA damage-
induced apoptosis.
Introduction
Apoptosis is a form of cell death orchestrated by chains
of biochemical reactions. Cells undergoing apoptosis
show characteristic morphological features such as
condensation of cytoplasmic and nuclear contents,
blebbing of plasma membranes, fragmentation of nu-
clei, and ultimately breakdown into membrane bound
apoptotic bodies that are rapidly phagocytized (Kerr et
al., 1972).
Mitochondria play an important role in regulating
apoptosis induced by intracellular damaging signals
such as DNA damage in mammalian cells (Danial and
Korsmeyer, 2004). Apoptotic stimuli exert their effects
on mitochondria to cause the release of proapoptotic
factors like cytochrome c and Smac/Diablo. These fac-
tors either directly activate caspases, a group of intra-
cellular cysteine proteases that execute apoptosis by
cleaving their substrates or releasing caspase inhibition
imposed by the inhibitor-of-apoptosis proteins (IAPs;
Du et al., 2000; Liu et al., 1996; Verhagen et al., 2000).
Mitochondrial response to apoptotic stimuli is regu-
lated by the pro- and antiapoptotic Bcl-2 family of pro-
teins (Gross et al., 1999; Martinou and Green, 2001).
Antiapoptotic proteins such as Bcl-2, Bcl-xL, and Mcl-1
protect mitochondrial integrity, while the proapoptotic*Correspondence: xwang@biochem.swmed.edumembers of the family promote the release of apopto-
genic proteins from mitochondria. The fate of a cell un-
der apoptotic stimulation is determined by the balance
between the pro- and antiapoptotic members of the
Bcl-2 family. Therefore, studying the regulation of such
balance will be critically important for our understand-
ing of apoptosis regulation.
Among the antiapoptotic members of the Bcl-2 family
proteins, Mcl-1 is unique in that it is an early-response
gene that can be rapidly induced and turned over (Ko-
zopas et al., 1993; Yang et al., 1995; Yang et al., 1996).
This property enables Mcl-1 to function at an early step
in a signaling cascade, consisting of Bcl-2 family pro-
teins, and provides an acute protective function against
apoptosis induced by a variety of stimuli, including
DNA damage, adenoviral infection, growth factors’
withdrawal, and treatment of cytotoxic agents (Cuco-
nati et al., 2003; Derouet et al., 2004; Huang et al., 2000;
Le Gouill et al., 2004; Nijhawan et al., 2003; Piret et al.,
2004; Zhang et al., 2002; Zhou et al., 1997). Consis-
tently, disappearance of Mcl-1 is associated with the
onset of apoptosis and is achieved by the combination
of synthesis blockage and continuous degradation (Cu-
conati et al., 2003; Nijhawan et al., 2003).
The degradation of Mcl-1 in HeLa cells can be
blocked by proteasome inhibitors, suggesting a role for
the ubiquitin proteasome pathway in apoptosis up-
stream of Bcl-2 family of proteins (Derouet et al., 2004;
Nencioni et al., 2004; Cuconati et al., 2003; Nijhawan et
al., 2003). In the current report, we demonstrate that
Mcl-1 is polyubiquitinated in vivo and in vitro. Using
HeLa cell extracts as a source, we established a cell-
free assay for Mcl-1 ubiquitination. Biochemical frac-
tionation of HeLa cell extracts allowed us to identify
and purify a 482 kDa E3 ubiquitin ligase that mediated
the polyubiquitination of Mcl-1. This protein turned out
to be a novel homologous to E6-AP carboxyl terminus
(HECT)-domain-containing ubiquitin ligase. We named
this protein Mule, for Mcl-1 ubiquitin ligase E3.
Results
Ubiquitination of Mcl-1 In Vivo and In Vitro
Proteins targeted for proteasome degradation are usu-
ally modified by a polyubiquitin chain (Hershko and
Ciechanover, 1998). To test whether Mcl-1 is ubiq-
uitinated, we treated HeLa cells expressing Flag-Mcl-1
with a proteasome inhibitor MG132 to block the pro-
teasome activity and performed immunoprecipitation
analysis for Flag-Mcl-1 to test for the accumulation of
higher-molecular-weight forms of Mcl-1 that could be
ubiquitin modified. As shown in Figure 1A, higher-
molecular-weight protein bands recognized by anti-
Mcl-1 antibody were indeed accumulated upon MG132
treatment (Figure 1A, lanes 3 and 4). To rule out a possi-
bility that these higher-molecular-weight bands were
from Mcl-1-associated protein rather than Mcl-1 itself,
the protein mixture was first heated in the presence of
1% SDS and 5 mM DTT to disassociate protein-protein
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wFigure 1. In Vivo and In Vitro Ubiquitination of Mcl-1
t(A) HeLa cells were mocked treated (lanes 1, 3, and 5) or treated
twith 10 M proteasome inhibitor MG132 (lanes 2, 4, and 6) for 8 hr,
tthen lysed in Flag lysis buffer. The cell extracts were immunopreci-
1pitated by anti-Flag mAb or control mouse IgG as described in the
4Experimental Procedures. Flag-Mcl-1-immune complex from the
aM2 beads was eluted by 3× Flag peptide (0.5 mg/ml) at 4°C over-
7night. Resulting eluants were either boiled in the presence of 1%
iSDS and 5 mM DTT or without treatment. The boiled eluant was
2diluted ten times then subjected to second immunoprecipitation
(with anti-Flag M2 agarose beads. The resulting eluants were sub-
djected to Western blotting with rabbit anti-Mcl-1 or Bim antibodies.
dMcl-1(Ub)n denotes ubiquitin conjugates of Mcl-1.itin provided us a tool to map the Mcl-1 ubiquitination
B) Mock- (lanes 1 and 3) or MG132-treated (lanes 2 and 4) HeLa
ells were lysed in Flag lysis buffer, and the cell extracts were im-
unoprecipitated by anti-Flag mAb or control mIgG. The immune
omplexes were eluted by 3× Flag peptide (0.5 mg/ml) at 4°C over-
ight. Resulting eluants were subjected to Western blotting with an
nti-ubiquitin antibody (P4D1 from Santa Cruz).
C) In vitro ubiquitination (Ub) assays were performed with in vitro
ranslated 35S-labeled Mcl-1. 35S-labeled Mcl-1 was incubated
ithout (lane 1) or with (lane 2) 3 l (20 g) HeLa cytosolic extracts
S100), as well as 0.8 l (0.3 g) of ubiquitin aldehyde, ATP-regener-
ting system, and 1.5 l (15 g) of GST-ubiquitin at 37°C for 1 hr in
final volume of 15 l adjusted with buffer A. The samples were
hen subjected to 10% SDS-PAGE and transferred to a nitrocellu-
ose filter. The filter was exposed to a Phosphorimaging plate for
6 hr at room temperature.
D) The same reaction was performed except that 1.5 l (15 g)
ethyl-ubiquitin was used instead of GST-ubiquitin.
E) In vitro ubiquitination assays were performed with 35S-labeled
ild-type Mcl-1 or mutants as described in (D). WT denotes wild-
ype Mcl-1 protein (lane 1); all R denotes Mcl-1 with all lysines mu-
ated to arginines (R) (lane 2); N3R denotes Mcl-1 with N-terminal
hree lysines mutated to arginines (R) (lane 3); 5/40R (lane 4), 40/
36R (lane 5), and 5/136R (lane 6) denote Mcl-1 with lysines 5/40,
0/136, and 5/136 mutated to arginines (R), respectively. N3R was
lso mutated in combination with middle five lysines (m5R) (lane
) or C-terminal five lysines (c5R) (lane 8); or in combination with
ndividual lysine residues 194/197R (lane 9), or 208R (lane 10), or
34R (lane 11), respectively.
F) Diagram of lysine residues for ubiquitination sites of Mcl-1. BH
enotes Bcl-2 homology region, and TM denotes transmembrane
omain.nteractions before being subjected to immunoprecipi-
ation. The disassociation was measured by the ab-
ence of Bim, a known Mcl-1-associated protein in the
mmunoprecipitates (Figure 1A, lanes 3–6, lower panel).
he heat treatment removed Bim from Mcl-1 immuno-
recipitate, but the higher shift of Mcl-1 bands re-
ained (Figure 1A, lanes 5 and 6). This result suggested
hat polyubiquitination of Mcl-1 might occur. The immu-
oprecipitates were also probed by an anti-ubiquitin
ntibody to verify that these higher-molecular-weight
ands were indeed caused by polyubiquitin conjuga-
ion of Mcl-1. As shown in Figure 1B, the higher-molec-
lar bands that were immunoprecipitated with anti-flag
ntibody were also recognized by the anti-ubiquitin an-
ibody, indicating that the shift of Mcl-1 protein bands
ere caused by polyubiquitin conjugation (Figure 1B,
ane 4).
We then established an in vitro ubiquitination assay
or Mcl-1. The system consists of an ATP regenerating
ystem, GST-ubiquitin or methylated ubiquitin (ubiquitin
as reductively methylated to prevent polyubiquitina-
ion chain formation as described by Carrano et al.
1999]), ubiquitin aldehyde to block the deubiquitin en-
ymes, radio-labeled recombinant human Mcl-1 protein
enerated by in vitro translation, and an S100 fraction
rom HeLa cells. As shown in Figures 1C and 1D, both
ST-ubiquitin and methylated ubiquitin were readily
onjugated to the radio-labeled Mcl-1. Furthermore,
ach component was indispensable for this ubiquitin
igating activity (data not shown).
apping Mcl-1 Ubiquitination Sites
his in vitro ubiquitination assay with methylated ubiq-
A BH3 Domain Containing Mcl-1 Ubiquitin Ligase
1087sites. In principle, methylated ubiquitin cannot be poly-
merized; therefore, each shifted band with the addition
of 7 kDa molecular mass is caused by ubiquitination on
a single site. If ubiquitin is present, excess amounts
of methylated ubiquitin can block polyubiquitin chain
formation, resulting in the formation of short polyubiq-
uitin chains. Since Mcl-1 was synthesized in vitro in re-
ticulocyte lysates and an S100 was utilized as a source
for ubiquitin ligase activity, polyubiquitin chains derived
from ubiquitin present in the reticulocyte lysates or the
S100 were terminated by methylated ubiquitin, produc-
ing short polyubiquitin chains (mono-, di-, and triubiqui-
tin; Figure 1D).
We used this assay in combination with site-specific
mutagenesis to examine which lysine residue(s) is re-
quired for Mcl-1 ubiquitination, and the data are shown
in Figure 1E. Mcl-1 contains total of 13 lysine residues
and could be ubiquitinated to multiple major upshifted
bands with an w7 kDa interval with methylated ubiq-
uitin in the HeLa S100 (Figure 1E, lane 1). None of these
ubiquitinated bands was formed when all the lysine res-
idues in Mcl-1 were mutated to arginines (Figure 1E,
lane 2).
When the first three lysine residues (5, 40, and 136)
were mutated, the majority of Mcl-1 ubiquitination was
eliminated, and only one major band remained (Figure
1E, lane 3). Among these three lysines, if lysine 136 was
intact, a strong short polyubiquitin chain was formed,
indicating that lysine 136 was one major ubiquitin tar-
get site (Figure 1E, lane 4). The short polyubiquitin
chain ligated to lysine 136 disappeared when lysine 136
was mutated (Figure 1E, lanes 5 and 6), and another
short polyubiquitin chain appeared (Figure 1E, lanes 5
and 6). This chain could be ligated to either lysine 5 or
40, since ablation of both sites blocked its formation
(Figure 1E, lane 3), but not when either one of them was
mutated (Figure 1E, lanes 5 and 6).
To search for additional sites beyond first three ly-
sines, we combined mutations at the first three lysines
with five lysine resides in the middle of Mcl-1, and this
change completely abolished Mcl-1 ubiquitination (Fig-
ure 1E, lane 7). In contrast, combining the aforemen-
tioned mutations with mutations in the last five lysine
residues showed the same ubiquitination pattern as the
first three lysine mutant alone, indicating that they did
not contribute to Mcl-1 ubiquitination (Figure 1E, lane
8). Among the five lysine residues in the middle of Mcl-1,
mutations at lysine 194 and 197 in combination with the
first three lysine mutants abolished ubiquitination, while
the mutations at the lysine residues 208 and 234 did
not have much effect (Figure 1E, lanes 9–11). Therefore,
five lysine residues (5, 40, 136, 194, and 197) in Mcl-1
protein are involved in ubiquitin conjugation (Figure 1F).
Consequently, mutations in these five lysine residues
lead to prolongation of Mcl-1 half-life (see Figure S1 in
the Supplemental Data available with this article on-
line). Among these five lysine residues, lysines 136, 194,
and 197 are conserved among human, mouse, and rat
(data not shown).
Identification of Mcl-1 Ubiquitination Activity
To isolate the enzyme that carries out Mcl-1 ubiquitina-
tion, we fractionated HeLa cell S100 extracts and re-constituted the Mcl-1 ubiquitination reaction using dif-
ferent column fractions. We found that the Mcl-1
generated by in vitro translation gave high background
in this assay. Therefore, we switched to the purified
bacterially expressed recombinant Flag-tagged Mcl-1
protein as a substrate. This modification dramatically
increased the specificity and sensitivity of the assay
since the Mcl-1 ubiquitin conjugates now could be de-
tected by anti-Flag antibody without interference from
reticulocyte lysates. The recombinant Mcl-1 could be
efficiently ubiquitinated by the ubiquitin ligase present
in the HeLa cell extracts (Figure 2A, lane 3).
Ubiquitin-protein ligation requires the sequential ac-
tion of three enzymes. The C-terminal Gly residue of
ubiquitin is activated in an ATP-requiring step by a
ubiquitin-activating enzyme, E1. Activated ubiquitin is
next transferred to an active-site Cys residue of a ubiq-
uitin-carrier protein, E2. Finally, the ubiquitin is linked
to the substrate by a ubiquitin-protein ligase, or E3 en-
zyme (Hershko and Ciechanover, 1998). Specificity of
ubiquitin-protein ligation and subsequent degradation
of target proteins appears to be determined through
selective interaction between specific E3s and protein
substrates (Varshavsky, 2000).
To study how many factors are involved in Mcl-1
ubiquitination, we first fractionated HeLa S100 through
an ion exchange Q column into four fractions: Flow-Figure 2. Fractionation and Reconstitution of Mcl-1 Ubiquitin Con-
jugating Activity
HeLa cell S100 was prepared and fractionated by Q-Sepharose into
four fractions (QFT [flow-through], Q15, Q30, and Q100 represent
eluant with 150 mM, 300 mM, and 1000 mM NaCl) as described in
the Experimental Procedures.
(A) QFT and bound fractions (Q15, Q30, and Q100) were collected
and dialyzed against buffer A. Aliquots of all four fractions (2 l
each; lane 4) or without QFT (lane 8), Q30 (lane 6), or Q100 (lane 5)
were incubated with an aliquot of methyl-ubiquitin (15 g in 1.5 l)
in the presence of Flag tagged Mcl-1 (200 ng in 2 l) at 37°C for 1
hr in a final volume of 15 l of buffer A. Mcl-1 alone (lane 1) and
the reaction mixture incubated with S100 (lane 2) are served as
negative and positive controls, respectively. The samples were then
subjected to Western blotting with a Flag antibody (M2).
(B) Recombinant E1 (15 ng in 0.25 l) and E2 (150 ng of Ubch7 in
0.3 l) were incubated alone (lane 2) or in combination with QFT
(lane 4), Q30 (lane 5), and Q100 (lane 6) in the presence of methyl-
ubiquitin (15 g in 1.5 l) and recombinant Mcl-1 (200 ng in 2 l) at
37°C for 1 hr in a final volume of 15 l. Reactions with HeLa S100
alone (lane 1) or with S100 plus all other ubiquitination assay com-
ponents as in (A) (lane 3) served as negative and positive controls,
respectively. The samples were then subjected to Western blotting
with an anti-Flag M2 antibody.
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1088through (QFT), proteins bound to the column and eluted t
tat 150 mM NaCl (Q15), 300 mM NaCl (Q30), and 1 M
NaCl (Q100), respectively. Three fractions, QFT, Q30, p
Uand Q100 were necessary and sufficient to catalyze the
Mcl-1 ubiquitination in this reaction (Figure 2A, lanes t
e4–8). Using a similar ion exchange column, it was re-
ported that majority of E2 activity is present in the QFT, b
twhile the E1 resides in the Q30 fraction (Hershko et al.,
1983). We therefore substituted Q30 activity with the n
spurified human E1 enzyme and the QFT fraction with
several purified recombinant human E2s. We found that a
ithe recombinant human E1 could indeed substitute for
the Q30 fraction, and one of the E2 enzymes, UbcH7, q
rcould substitute the QFT fraction (data not shown).
However, E1 and UbcH7 were not sufficient for the p
oMcl-1 ubiquitin ligase activity (Figure 2B, lane 2). Addi-
tion of the Q100 fraction, rather than QFT or Q30, to t
cthe reaction containing E1 and UbcH7, restored Mcl-1
ubiquitin ligase activity, indicating that the Q100 frac-
ntion contained an E3 enzyme for Mcl-1 ubiquitination
(Figure 2B, lanes 4–6). We referred to this Mcl-1 ubiq- a
Huitin E3 ligase activity present in the Q100 fraction as
Mule for Mcl-1 ubiquitin ligase E3. c
W
2Biochemical Purification of Mule
Using Mcl-1 ubiquitination as an assay, we purified the a
dMule activity from the Q100 to apparent homogeneity
through a six step procedure (Figure 3A; see the Experi- (
Bmental Procedures for details). The last step of purifica-
tion, a Mono Q column chromatographic step, is shown N
Din Figures 3B and 3C. Mule activity was eluted from the
Mono Q column at roughly 400 mM NaCl (Figure 3C, t
dfractions 10 and 11). The same protein fractions were
subjected to SDS-PAGE followed by Colloidal blue (
Mstaining. A protein band with a molecular mass much
larger than the highest molecular weight standard used s
9(207 kDa) correlated with the Mcl-1 ligase activity (Fig-
ure 3B). d
RMolecular Cloning of Mule
To obtain the sequence identity of this Mcl-1 ubiquitin A
aligase activity, the protein was excised from the gel and
subjected to tryptic digestion followed by mass spectral c
panalysis. The mass fingerprinting of the digested pep-Figure 3. Purification of Mcl-1 Ubiquitin Li-
gase E3 (Mule)
(A) Diagram of the purification scheme for
Mule. See the Experimental Procedures for
details.
(B) Aliquots (30 l) of the indicated fractions
from the Mono Q column were subjected to
6% SDS-PAGE followed by Colloidal blue
staining using a Colloidal blue staining kit
from Invitrogen.
(C) Aliquots of 4 l of the indicated Mono Q
column fractions were incubated with 1.5 l
(15 g) of Methyl-Ub, 0.25 l (15 ng) of hu-
man E1, 0.3 l (150 ng) of Ubch7, 0.8 l (0.3
g) of ubiquitin aldehyde, and ATP-regener-
ating system at 37°C for 1hr in a final volume
of 15 l adjusted with buffer A. After 1 hr at
37°C, the samples were subjected to West-
ern blotting using a rabbit anti-Mcl-1 an-
tibody.ides was initially mapped to a previously reported pro-
ein Ureb1, a 310 amino acid HECT-domain-containing
rotein (Gu et al., 1994). But it was quite apparent that
reb1 did not represent Mule in its entity because of
he size difference. We subsequently performed sev-
ral rounds of BLAST searching using the NCBI gene-
ank and TIGR human gene index (http://www.tigr.org/
igr-scripts/tgi/T_index.cgi?species=human) in combi-
ation with a Genome Scan using the human genomic
equence (http://genes.mit.edu/genomescan.html) to
ssemble the full-length Mule sequence (see the Exper-
mental Procedures). The finally assembled Mule se-
uence based on these resources is 4374 amino acid
esidues long (Figures 4A and S2). Furthermore, the
eptides we identified with mass spectrometry technol-
gy using the purified endogenous Mule were matched
hroughout the newly assembled full-length Mule, in-
luding the new N terminus (Figure S2).
The 4374 amino acid Mule contains multiple recog-
izable domains (Figure 4A). The COOH-terminal 350
mino acid residues were well conserved among the
ECT ubiquitin ligase domains (Figure 4B). Mule also
ontains a ubiquitin-associated (UBA) domain and a
WE domain in the middle of the protein (Aravind,
001; Hofmann and Bucher, 1996). In between the WWE
nd the HECT domains, there is a well-conserved BH3
omain that is shared by all the Bcl-2 family of proteins
Figure 4C), and none of the sequence matching with
H1, BH2, and BH4 domains was found in Mule. At the
terminus of Mule, there are two unclassified domains:
UF, for domain of unknown function. From the struc-
ure analysis, these two domains resemble ARM (Arma-
illo)-like repeats; therefore we named them as ARLD1
ARM repeat-like domain 1) and ARLD2 (Figure 4A).
ule is highly conserved in mammals. The amino acid
equence among human and mouse share more than
0% identity throughout the entire protein, and all the
omains are well conserved (Figure S3).
ecombinant Activity of Mule
fter cloning of the putative full-length Mule, we gener-
ted and purified recombinant Mule protein using a ba-
ulovirus-based expression system (Figure 5A). In the
resence of E1, Ubch7 (E2), and an ATP-regenerating
A BH3 Domain Containing Mcl-1 Ubiquitin Ligase
1089Figure 4. Domain Structure of Mule
(A) A schematic representation of Mule is shown by the horizontal bar with the numbers corresponding to the amino acid residues. The
predicted Mule is 4374 amino acids long. The Arm repeat-like domains (ARLD) 1 and 2, the WWE domain, the UBA domain, the BH3 domain,
and the HECT domain are indicated.
(B) The amino acid sequence of the HECT domain of Mule was aligned with HECT domains of human E6-AP, budding yeast TOM1, and
human NEDD4 by the T-coffee program (Notredame et al., 2000). Identical amino acids and conserved amino acids are marked by black and
gray boxes, respectively. The cystine residues in the active site for HECT domains are marked in red.
(C) The amino acid sequence of the BH3 domain of Mule was aligned with the BH3 domains of human Bcl-2 family proteins by the T-coffee
program. Identical amino acids and conserved amino acids are marked by black and gray boxes, respectively.system, the purified recombinant Mule was able to
stimulate Mcl-1 ubiquitination with methylated or GST-
tagged ubiquitin, but not with a ubiquitin-like protein
SUMO (Figure 5B). We used methylated ubiquitin for
further biochemical analysis because it gave clearer
signal. Mule ubiquitinated Mcl-1 in a dose-dependent
manner, and the ubiquitination activity relied on the
presence of E1 and E2 (Figure 5C).
To further confirm that the HECT domain was re-
quired for E3 activity, the active-site Cys residue that
was deduced from conservation among various HECT
domain E3s (Figure 4B) was mutated to an Ala by site-
specific mutagenesis. The mutant Mule was purified
through the same procedure as wild-type Mule. In con-
trast to wild-type Mule, the point mutant lost E3 activity
for Mcl-1 (Figure 5D, lanes 1–3). Furthermore, the Cys
mutant Mule showed no dominant-negative effect over
wild-type Mule on Mcl-1 ubiquitin ligase activity (Figure
5D, lanes 4–9).
The members of the Bcl-2 family of proteins contain-
ing only the BH3 domain use this domain to interact
with other family members. If Mule also uses its BH3
domain to interact with Mcl-1, a peptide containing this
domain should compete for Mule-Mcl-1 interaction,
therefore blocking Mcl-1 ubiquitination in the reconsti-
tuted system. To test this hypothesis, we synthesized
a 26 amino acid Mule BH3-containing peptide and a
mutant peptide in which four hydrophobic residues re-
quired for protein-protein interaction were switched
with glutamates (4E). As shown in Figure 5E, the Mule
BH3 peptide can efficiently block Mcl-1 ubiquitination
at 4 M (Figure 5E, lane 4), while the Mule BH3-4E mu-tant has no obvious effect even at 20 M (Figure 5E,
lane 9).
To further confirm that Mule can promote Mcl-1
polyubiquitination, we used wild-type ubiquitin to per-
form an Mcl-1 in vitro ubiquitination assay. Mule stimu-
lates Mcl-1 polyubiquitination in the presence of E1 and
E2 (Figure 5F, lanes 3–7 and 9). Mutation of the active
cystine site abrogates ubiquitin ligase activity (Figure
5F, lane 8). Addition of BH3 peptide rather that 4E mu-
tant blocked Mcl-1 polyubiquitination (Figure 5F, lanes
10–13).
Characterization of Interaction
between Mule and Mcl-1
We generated a monoclonal antibody against the bac-
terially expressed Mule (amino acids 2219–2396) and
performed Western blotting and immunoprecipitation
experiments with this antibody. This antibody specific-
ally recognizes the 482 kDa band in human cell extracts
(data not shown). The specificity of this antibody was
confirmed by either antigen competition or small RNA
interference (data not shown and Figure 7). Mule was
unstable upon high-temperature treatment displaying
significant breakdown products when boiled in SDS-
PAGE loading buffer (data not shown).
Having an antibody that recognizes the endogenous
protein allowed us to specifically deplete Mule from the
HeLa extracts. As shown in Figures 6A and 6B, deple-
tion of Mule with this anti-Mule monoclonal antibody
dramatically compromised Mcl-1 ubiquitination in the
extracts, indicating that Mule is the major E3 for Mcl-1
in HeLa cell extracts (Figures 6A and 6B, lane 2). In
Cell
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Ubiquitination Using Recombinant Mule
(A) N-terminal His12-tagged Mule was ex-
pressed using a baculovirus expression sys-
tem and purified as described in the Experi-
mental Procedures. 0.8 g of recombinant
Mule was subjected to 6% SDS-PAGE fol-
lowed by Colloidal blue staining using a Col-
loidal blue staining kit from Invitrogen.
(B) Recombinant Mule was incubated with
ATP regenerating buffer, E1, E2, recombinant
Mcl-1, and ubiquitin in a 10 l reaction vol-
ume at 37°C for 1 hr. The reactions were per-
formed as duplicates in lanes 4 and 5, 7 and
8, and 10 and 11. Methyl-Ub (125 M) was
used in lanes 2–5, GST-Ub (125 M) in lanes
6–8, and GST-SUMO (125 M) in lanes 9–11.
(C) Mcl-1 ubiquitination reactions were per-
formed in the presence of methyl-Ub using
two different doses of Mule (lane 2, 1×—15
nM and lane 3, 4×—60 nM) as above. As
shown in lanes 4–6, the in vitro ubiquitination
reactions were performed in the absence of
Mule (lane 4), E2 (lane 5), or E1 (lane 6) and
analyzed as described in the Experimental
Procedures.
(D) Recombinant Mule-C4341A mutant pro-
tein was added to the Mcl-1 ubiquitination
reaction at different doses (0 nM—lanes 4
and 7; 10 nM—lanes 1, 5, and 8; 20 nM—
lane 2; 35 nM—lanes 3, 6, and 9) without
wild-type recombinant Mule (rMule, lanes
1–3), or with 5 nM rMule (lanes 4–6), or with
10 nM rMule (lanes 7–9) and analyzed as de-
scribed in the Experimental Procedures.
(E) A Mule BH3 peptide or a Mule BH3-4E
mutant peptide was added to the Mcl-1
ubiquitination reaction at different doses (0
nM—lane 1, 0.16 M—lanes 2 and 6, 0.8
M—lanes 3 and 7, 4 M—lanes 4 and 8, 20
M—lanes 5 and 9) with wild-type recombinant Mule (rMule, 10 nM).
(F) Mcl-1 ubiquitination reactions were performed in the presence of ubiquitin instead of methyl-Ub to visualize polyubiquitin chain formation.
The reaction mixture is subjected to immunoprecipitation by anti-Flag M2 beads followed by Western blotting with rabbit anti-Mcl-1 antibody.
Mcl-(Ub)n denotes ubiquitin conjugates of Mcl-1.contrast, the same depletion experiment performed B
twith another monoclonal antibody against β-tubulin did
not deplete Mcl-1 ubiquitin ligase activity (Figures 6A t
fand 6B, lane 1).
We next tested whether Mule interacts with Mcl-1 in B
bvivo. Cell extracts from Flag-Mcl-1-expressing cells
were immunoprecipitated with an anti-Flag monoclonal a
antibody. The immunoprecipitates were then subjected
to SDS-PAGE and immunoblotted with antibodies against E
aFlag or Mule. As shown in Figure 6C, the antibody
against Flag precipitated Flag-Mcl-1 in Flag-Mcl-1- T
dexpressing cells, but not in the control cells (Figure 6C,
lower panel, lanes 1 and 2). The Flag antibody also R
oprecipitated Mule, and the amount of coprecipitated
Mcl-1 and Mule increased upon MG132 treatment (Fig- n
aure 6C, upper panel, lanes 2 and 3). These results indi-
cate that Mcl-1 interacts with Mule in vivo. l
tTo examine whether the BH3 domain of Mule is suffi-
cient for interaction with Mcl-1, we used a biotin- a
slabeled version of the 26 amino acid Mule BH3 peptide
and the 4E mutant to pull down proteins from cell ex- o
utracts. As shown in Figure 6D, Mule BH3 domain speci-
fically pulled down Mcl-1, but not Bcl-xL, Bcl-2, and max in HeLa S100 (Figure 6D, lane 3), while no interac-
ion between Mule BH3-4E mutant with Mcl-1 was de-
ected (Figure 6D, lane 4). In contrast, the BH3 peptide
rom another proapoptotic BH3-only containing protein
im was able to pull down all four proteins as reported
efore (Figure 6D, lane 5; Harada et al., 2004; Chen et
l., 2005).
ffects of Mule on Mcl-1 Degradation
nd Apoptosis
o confirm that Mule was responsible for Mcl-1 degra-
ation in vivo, we eliminated Mule expression by an
NA interference approach. Transient expression of each
f four different siRNAs against Mule was able to elimi-
ate the majority of Mule; however, two or three days
fter transfection, residual Mule still could be detected,
ikely due to its long half-life or limitations of transfec-
ion efficiency (data not shown). Long-lived proteins are
lways difficult to be manipulated by a transient siRNA
trategy. We therefore established a stable cell line that
nly expressed small hairpin RNA (shRNA) against Mule
pon addition of tetracycline. Cell growth was not dra-
atically affected by tetracycline addition (data not
A BH3 Domain Containing Mcl-1 Ubiquitin Ligase
1091Figure 6. Mule Is the Major E3 for Mcl-1
Ubiquitin Ligase Activity and Interacts with
Mcl-1 through the BH3 Domain
(A) Immunodepletions were performed in
HeLa S100 with the use of the control anti-
β-tubulin monoclonal antibody (lane 1) or
anti-Mule monoclonal antibody (lane 2). Mule
protein was detected in the supernatants by
Western blotting with the use of the corre-
sponding antibody.
(B) Aliquots of 10 g HeLa S100 immunode-
pleted with the β-tubulin (lane 1) or anti-Mule
monoclonal antibodies (lane 2) were used for
Mcl-1 in vitro ubiquitination assay. A probe
alone served as a control (lane 3). The reac-
tion mixtures were subjected to Western
blotting with anti-Flag M2 antibody.
(C) Interaction of Mule and Mcl-1 in vivo.
Control HeLa cells (lane 1) or HeLa cell sta-
ble expression Flag-tagged Mcl-1 (lanes 2
and 3) and were treated without (lane 2) or
with MG132 (lane 3). Cells were lysed in Flag
lysis buffer. Cell extracts were immunopreci-
pitated by anti-Flag mAb. Aliquots of 20 l of
immunoprecipitates were subjected to West-
ern blotting with anti-Mule or anti-Mcl-1 anti-
body as marked.
(D) BH3 domain of Mule selectively interacts
with Mcl-1. Ten micromolar biotin-labeling
Mule BH3, Mule BH3-4E, and Bim BH3 pep-
tides were incubated with HeLa cell extracts at 4°C for 2 hr and then precipitated with streptavidin agarose beads (Novagen) overnight in
Flag lysis buffer. Aliquots of 20 l of immunoprecipitates were subjected to Western blotting with antibody against Mcl-1, Bcl-xL, Bcl-2,
and Bax.shown). This inducible shRNA approach provides supe-
rior knockdown efficiency and broadened the time win-
dow to evaluate the cellular effect on Mule depletion.
To increase knockdown efficiency, we also increased
the copy number of shRNA driven by H1 promoter from
one to seven (Figure 7A).
Mule expression was eliminated by tetracycline in a
time-dependent fashion. After induction of the tetracy-
cline for three days, Mule levels became completely
undetectable (Figures 7A and 7B). At the same time,
Mcl-1 gradually accumulated, and its level of increase
correlated well with diminishing Mule (Figure 7A, lower
panel). In contrast to Mcl-1, the levels of the other
Bcl-2 family of proteins including Bcl-xL, Bcl-2, Bax,
Bak, Bim, Bid, and a control protein actin did not
change upon elimination of Mule, a result that was con-
sistent with the specificity of the Mule BH3 domain for
Mcl-1 (Figure 7C). Accordingly, half-life of Mcl-1 was
prolonged in Mule knockdown cells with or without
apoptotic stimuli (Figure S4). We then treated cells with
their Mule level knocked down with several DNA-dam-
aging agents including UV irradiation and two com-
monly used chemotherapeutic drugs etoposide and
cisplatin. As shown in Figure 7C, cell death induced by
all three agents was reduced when Mule was knocked
down. The cell death was correlated well with the cas-
pase-3-like (DEVD) activity (Figure 7D). Among these
DNA-damaging agents, cisplatin showed the least abil-
ity to induce apoptosis when Mule was knocked down.
We therefore performed a detailed biochemical analysis
in cells treated with this drug with or without Mule
knocked down. In cells in which Mule was there, we
started to observe caspase-3 activation as measuredby its cleavage into active form 4 hr after cisplatin treat-
ment, and it continued to increase up to 8 hr (Figure
7E, lanes 1–5), while in cells that Mule was knocked
down, we did not see any caspase-3 activation even 6
hr after cisplatin treatment. Only after 8 hr did we start
to see weak caspase-3 activation (Figure 7E, lanes
6–10). Consistently, the cleavage of endogenous cas-
pase-3 substrate poly(ADP-ribose) polymerase, PARP,
showed the same pattern. However, Mule protein level
did not change significantly upon cisplatin treatment.
To test whether the delayed apoptosis when Mule
was knocked down has a long-lasting effect, cells were
switched to fresh medium after 6 hr of cisplatin treat-
ment and continued in culture for 8 days. As shown in
Figure 7F, there were few, if any, colonies grown up after
cells containing Mule were treated with cisplatin. In
contrast, there were more than 9-fold more colonies
that appeared after the same treatment after Mule was
knocked down.
Discussion
Mule Is the E3 Ubiquitin Ligase for Mcl-1
Although Mule is an E3 ubiquitin ligase that is identified
solely based on its in vitro biochemical activity, we be-
lieve that it is the enzyme that regulates Mcl-1 half-life
in vivo. First, it seems to contribute to the major Mcl-1
ubiquitination activity in HeLa cell extracts since immu-
nodepletion of this protein with a specific monoclonal
antibody also depleted most of the activity. Second,
four different siRNA oligonucleotides that target dif-
ferent regions of Mule mRNA specifically knocked
down Mule protein with a corresponding increase in
Cell
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t(A) Scheme of tetracycline-inducible Mule shRNA construct (see
the Experimental Procedures for detail). Mule shRNA was induced s
by adding 2 g/ml tetracycline to the culture medium of a U2OS a
cell line stably transfected with pcDNA6/TR and pSuperior/Mule- i
shRNA. Treated cells were collected in lysis buffer at indicated
ttime, and cell extracts were subjected to SDS-PAGE and subse-
aquent Western blotting for Mule, Mcl-1, and actin.
a(B) The same samples in (A) were subjected to 15% SDS-PAGE and
subsequent Western blotting for Mcl-1, Bcl-xL, Bcl-2, Bim, Bax, u
Bak, and Actin. M
(C) U2OS cells with pcDNA6/TR and pSuperior/Mule-shRNA stably e
transfected were treated with or without tetracycline for 3 days fol-
olowed by treatment of UV irradiation at 0, 20, and 40 mJ/cm2, eto-
poside at 0, 50, 100 g/ml for 20 hr, or cisplatin at 0, 100, 200 M
ofor 20 hr. Cell death (% of total population) was quantified by Try-
pan blue staining. Values and error bars represent the average and (
standard derivation of three independent experiments. a
(D) U2OS cells with pcDNA6/TR and pSuperior/Mule-shRNA stably c
transfected were treated with or without tetracycline for 3 days fol-
ilowed by treatment of UV irradiation at 0, 20, and 40 mJ/cm2, etopo-
uside at 0, 50, 100 g/ml for 20 hr, or cisplatin at 0, 100, 200 M for
20 hr. Cell extracts were collected in lysis buffer and applied to the
fluorogenic assay for capase-3 activity as described in the Experi-
mental Procedures. The caspase-3 activity was expressed as RFU
(relative fluorescence units)/min/mg protein. Values and error bars (
represent the average and standard derivation of three indepen- T
dent experiments. p
(E) U2OS cells with pcDNA6/TR and pSuperior/Mule-shRNA stably w
transfected were treated with or without tetracycline for 3 days fol- 1
lowed by treatment of cisplatin at 200 M for 0, 2, 4, 6, and 8 hr. s
Cell extracts were collected and subjected to Western blotting for u
Mule, Mcl-1, caspase-3, PARP, and actin. fp the Mcl-1/Bak complex and promotes Mcl-1 degra-
F) Long-term survival of Mule knockdown cells upon DNA damage.
wo thousand U2OS cells (in 150 mm plates) with pcDNA6/TR and
Superior/Mule-shRNA stably transfected were treated with or
ithout tetracycline for 3 days followed by treatment of cisplatin at
0 M for 6 hr. The number of colonies formed after 8 days was
cored and present as relative percentage to colonies formed in
ntreated cells. The data represent the average number of colonies
ormed from at least two experiments.cl-1 protein levels (data not shown). And finally, an
nducible shRNA construct stably transfected into cells
onfirmed increased Mcl-1 protein levels that perfectly
orrelated with the induction of shRNA for Mule (Fig-
re 7).
Mule belongs to the HECT-domain-containing group
f E3 ligases. The HECT domain was first identified in
he enzyme that binds to the papilloma virus E6 protein
esponsible for degradation of the p53 tumor suppres-
or protein (Huibregtse et al., 1995). The active site Cys
ithin the HECT domain receives ubiquitin from the
orresponding E2 and transfers it to the protein sub-
trate (Scheffner et al., 1995). Mutation of the con-
erved Cys in the HECT domain of Mule abolishes its
cl-1 ubiquitination activity (Figure 5D). Mule also con-
ains recognizable UBA and WWE domains. Both do-
ains are commonly found in other E3 enzymes. The
BA domain is known to bind mono- or polyubiquitin,
nd the WWE domain is a conserved globular domain
hat is predicted to mediate specific protein-protein in-
eractions in ubiquitin and ADP-ribose conjugation sys-
ems (Aravind, 2001; Hofmann and Bucher, 1996; Wil-
inson et al., 2001).
But the precise roles of these three domains, as well
s the two ARM repeat-like domains (ARLD1 and
RLD2) at the Mule N terminus, remain to be defined by
urther structure-function studies. In addition to these
ecognizable domains, the other regions in this enor-
ous protein may serve other unknown functions as
ell.
ule Is a New Member of BH3-Only
roapoptotic Proteins
nterestingly, Mule also contains a well-conserved BH3
omain through which the Bcl-2 family members in-
eract with each other (Figure 4C; Kelekar and Thomp-
on, 1998). The BH3 domain of Mule seems to function
s its substrate binding surface specific for Mcl-1. Sim-
lar mutations in the BH3 domain that abolish the func-
ion of other BH3-ohly proteins (4E) also eliminate the
bility of Mule BH3-containing peptide to bind Mcl-1
nd inhibit Mcl-1 ubiquitination catalyzed by Mule (Fig-
re 5E; Chen et al., 2005). In addition, elimination of
ule attenuates apoptosis upon DNA damage. All this
vidence qualifies Mule as a novel member of BH3-
nly, proapoptotic family proteins.
Among the Bcl-2 family members, the BH3 domain
f Mule mostly resembles to the BH3 domain of Bak
Figure 4C). Not surprisingly, Bak has been found to be
ssociated with Mcl-1 (Cuconati et al., 2003). It is con-
eivable that Mule not only binds to free Mcl-1 through
ts BH3 domain but also competes with Bak to break
A BH3 Domain Containing Mcl-1 Ubiquitin Ligase
1093dation in the proteasome. The recognition of Mcl-1 by
Mule seems to be specific, as the case of other BH3-
only containing proteins (Figure 6D; Chen et al., 2005),
and we did not observe any interaction between the
BH3 domain of Mule with other anti- or proapoptotic
Bcl-2 proteins, including Bcl-2, Bcl-xL, and Bax. The
level of these proteins also did not change when Mule
was knocked down.
Regulation of Mcl-1 Level by Proteolysis
As an E3 ligase for Mcl-1, Mule is the first such enzyme
specifically identified that regulates the Bcl-2 family of
proteins. Since Mcl-1 functions at an early step in apo-
ptosis induced by various death stimuli and serves as
a major survival factor, the activity that regulates Mcl-1
levels could be critically important in many physiologi-
cal and pathological situations. The importance of Mcl-1
during development and lymphocytes homeostasis has
been demonstrated by gene knockout studies. Deletion
of the Mcl-1 gene from the mouse genome leads to
peri-implantation embryonic lethality (Rinkenberger et
al., 2000). Conditional knockout of Mcl-1 in mouse thy-
mus and spleen results in profound reduction of both
B and T cells (Opferman et al., 2003). Mcl-1 is also obli-
gate for the survival of hematopoietic stem cells (Op-
ferman et al., 2005). In mice, Mcl-1 overexpression
apparently sets the stage for the development of lym-
phomas, very much like overexpression of Bcl-2 does
(Reed, 1997). At the cellular level, Mcl-1 is a target of
a viral oncogene (E1A) and for several survival factors
including MCSF, VEGF, stem cell factor and interleu-
kin-5, and HIF (Cuconati et al., 2003; Derouet et al.,
2004; Huang et al., 2000; Le Gouill et al., 2004; Nijhawan
et al., 2003; Piret et al., 2004; Zhang et al., 2002; Zhou
et al., 1997). Overexpression of Mcl-1 has been found
in a variety of human malignancies and often correlates
with adverse clinical outcome (Zhang et al., 2002). Dys-
function of Mule is a potential reason for accumulation
of Mcl-1. The function of Mule in tumor suppression
will be addressed after the establishment of a murine
knockout model and large-scale screening of human
cancer patients for Mule mutations.
As important as Mcl-1 is, there seems to be other
activities in addition to Mule that proteolyses Mcl-1. For
example, it has been reported that Mcl-1 is a caspase
substrate; a property that may contribute to the feed-
forward amplification of apoptotic signals once cas-
pases are activated (Clohessy et al., 2004; Herrant et
al., 2004; Weng et al., 2005). In addition, we have ob-
served that in several cell lines upon apoptosis induc-
tion, Mcl-1 still decreased even in the presence of pro-
teasome or caspase inhibitors or when Mule level was
knocked down to an undetectable level (Figure 7 and
data not shown). So there might be another DNA-dam-
aging inducible protease that cleaves Mcl-1 and also
contributes to the onset of apoptosis in addition to
Mule and caspases. Such a protease may contribute to
the difference in half-life when cells were treated with
cisplatin in the presence and absence of Mule (Figure
S4). Nevertheless, the Mule knockdown experiment
provides strong evidence that regulation of Mcl-1 by
Mule through proteasomal degradation is a major con-
tributor for the prosurvival role of Mcl-1 upon DNAdamage, and this notion will be further consolidated
and extended as soon as an animal model is estab-
lished.
Biological Functions of Mule
Mule is the first ubiquitin E3 ligase that has been iden-
tified solely based on its biochemical activity to carry
out the ubiquitination on Mcl-1. It is therefore possible
that there are other Mule substrates in cells. More im-
portantly, if there are other substrates for Mule, whether
the degradation of these proteins is coordinated biolo-
gically with the degradation of Mcl-1 will be an interest-
ing question for future studies.
With the inducible RNAi knockdown cells at hand and
an anticipated animal model with Mule knocked out,
we can start to address this interesting question.
Experimental Procedures
Reagents
The following antibodies were used for Western blots: monoclonal
anti-Mcl-1 (Pharmingen), polyclonal anti-Mcl-1 (Santa Cruz), poly-
clonal anti-Bcl-2 (Ancell), polyclonal anti-Bax (Santa Cruz), poly-
clonal anti-Bak (Santa Cruz), polyclonal anti-Bim (Pharmingen),
polyclonal anti-Bcl-xL (Pharmingen), polyclonal anti-caspase-3
(Cell signal), polyclonal anti-actin (Sigma), and anti-ubiquitin P4D1
monoclonal antibody (Santa Cruz). Anti-Mule monoclonal antibody
was generated against the bacterially expressed His-tagged Mule
(amino acids 2219–2396) from University of Texas Southwestern
antibody core facility. Immunoprecipitations for Flag-Mcl-1 were
performed with monoclonal antibody to Mcl-1 or Flag (Sigma).
MG132, caspase-3 fluorogenic II substrate, phosphatase inhibitor
cocktail II, and protease inhibitors were all obtained from Calbio-
chem. siRNA against Mule (si5635 TGCCGCAATCCAGACATAT,
si9931 CATACCGAGAAGCATGCAA, si1301 GAGTGGTTGACCTTAT
CAC, si1826 GTGCACTCTGTTTGAATGC, si2206 CAGGCCATGCA
GAGCTTTA) were ordered from Dharmacon and University of Texas
Southwestern RNA oligosynthesis core facility and used following
the manufacturer’s protocols. N-terminal biotin labeled Mule BH3
peptide (PGVMTQEVGQLLQDMGDDVYQQYRSL) and Mule BH3-4E
peptide (PGVMTQEEGQLEQDEGDDEYQQYRSL) were ordered from
New England Peptide. Biotin-labeled Bim BH3 peptide (DMRPEI
WIAQELRRIGDEFNAYYARR) is ordered from University of Texas
Southwestern peptide synthesis core facility.
In Vitro Ubiquitination Assay
In a 15 l reaction, 200 ng of recombinant Flag-Mcl-1 was incu-
bated with an ATP regenerating system (50 mM Tris [pH 7.6], 5 mM
MgCl2, 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml of creatine
kinase), 10 g of methyl-ubiquitin, 10 ng human E1, 100 ng Ubch7,
2 M of ubiquitin aldehyde, and 10 g of S100 or designated frac-
tions at 37°C for one hour. After terminating the reactions with SDS
sample buffer, reaction products were fractionated by SDS-PAGE
(10%) and analyzed by Western blotting with anti-Flag M2 antibody
during purification and anti-Mcl-1 when purified components were
used.
Generating Inducible Mule shRNA Cell Line
Mule shRNA sequence si5635 (TGCCGCAATCCAGACATAT) was
annealed following the protocol from Oligoengine and cloned into
BglII and HindIII sites of pSuperior.puro vector (Oligoengine). The
histone H1 promoter and shRNA was released from pSuperior.puro.
shRNA construct and subcloned into pBluescript (modified) at sites
of EcoRI and HindIII. The H1 promoter and shRNA were released
from the pBluescript Mule shRNA constructs at the sites of BamHI
and BglII and reinserted into the pBluescript Mule shRNA vector
linearized with BglII to generate multiple copies of H1 + shRNA
cassette. This cloning strategy was repeated several rounds until
seven tandem cassettes were inserted into the same vector. These
seven cassettes were then cloned into the BamHI site of the pSup-
erior.puro vector (modified without H1 promoter).
Cell
1094The Mule shRNA construct was cotransfected with tetracycline H
Srepressor expression construct into 5 × 105 attached U2OS cells
grown in DMEM with 10% FBS using Lipofectamine transfection p
areagent (Invitrogen) according to the manufacturer’s protocol. One
day later, the cells were selected against 1 g/ml blasticidine and H
2 g/ml puromycin. After two weeks, individual clones were lifted L
and tested for expression of tetracycline repressor. Positive clones i
were further tested for Mule shRNA expression. Clones were g
treated with 2 g/ml tetracycline for 3 days. Cell extracts were col-
H
lected and subjected to 6% SDS-PAGE and Western blotting with
A
anti-Mule monoclonal antibody. Clones with the best inducible
Hknockdown of Mule were chosen for further experiments.
p
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8Supplemental Data
HSupplemental Data include four figures and Supplemental Experi-
mmental Procedures and can be found with this article online at
whttp://www.cell.com/cgi/content/full/121/7/1085/DC1/.
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